2025-01-14 - Analysis Report
## Colgate-Palmolive Co (CL) Stock Analysis Report

**1. Performance Comparison and Divergence:**

Colgate-Palmolive Co (CL) is a consumer goods company that manufactures and sells oral hygiene products, personal care products, and pet nutrition products.

The cumulative return of CL (33.12%) significantly lags behind the S&P 500 (VOO) cumulative return (112.47%).  The difference is a substantial -79.4%, placing it in the 4.8th percentile of its historical range of performance relative to the S&P 500.  This indicates considerable underperformance compared to the broader market.

The provided CAGR (Compound Annual Growth Rate) data shows inconsistent performance over the analyzed periods, ranging from a negative return of -12% to a high of 32%.  The Alpha consistently hovers around 0.2, suggesting a small degree of outperformance relative to the market benchmark. However, the Beta values fluctuate (42-74), implying varying levels of market sensitivity throughout these periods.  The market capitalization (Cap(B)) also exhibits growth over time.

**2. Recent Price Movement:**

* **Closing Price:** $87.10
* **5-Day Moving Average:** $87.17
* **20-Day Moving Average:** $90.89
* **60-Day Moving Average:** $93.63

The stock is currently trading below its 5, 20, and 60-day moving averages, suggesting a downtrend.

**3. Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 16.32 – This indicates the stock is significantly oversold.
* **PPO (Price Oscillator):** -0.50 – This also suggests bearish momentum.
* **20-Day Relative Divergence Change:** +3.0 – This points to a short-term upward trend, potentially a short-lived bounce.
* **Expected Return:** -930.5% – This extremely negative expected return is concerning and requires further investigation into its calculation and assumptions. It is highly improbable.

The current price of $87.10, being below the moving averages, suggests a lack of immediate upward momentum despite the short-term positive divergence.  No significant price surge or drop is immediately evident from the provided data. The extremely negative expected return needs clarification.

**4. Recent Earnings Analysis:**

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2024-10-25 | $0.9 | $5.03B      |
| 2024-07-26 | $0.89 | $5.06B      |
| 2024-04-26 | $0.83 | $5.07B      |
| 2023-10-27 | $0.86 | $4.92B      |
| 2024-10-25 | $0.86 | $4.92B      | *(Duplicate entry, likely an error)*

Earnings appear relatively stable, with slight fluctuations in EPS and revenue.  The duplicated entry needs correction. Further analysis requires more complete and accurate data.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2024-09-30 | $5.03B      | 61.08%        |
| 2024-06-30 | $5.06B      | 60.62%        |
| 2024-03-31 | $5.07B      | 60.00%        |
| 2023-12-31 | $4.95B      | 59.60%        |
| 2023-09-30 | $4.92B      | 58.54%        |

Revenue remains relatively consistent, with minor fluctuations. Profit margins are high and show a slight downward trend.

**Capital and Profitability:**

| Quarter | Equity       | ROE           |
|---------|--------------|---------------|
| 2024-09-30 | $0.43B       | 169.43%       |
| 2024-06-30 | $0.12B       | 594.31%       |
| 2024-03-31 | $0.23B       | 296.96%       |
| 2023-12-31 | $0.61B       | 117.90%       |
| 2023-09-30 | $-0.01B      | -7866.67%     |

Equity and ROE figures show significant volatility and an outlier in 2023-09-30, requiring further investigation to understand the reasons behind such extreme values.

**7. Overall Analysis:**

Colgate-Palmolive shows stable revenue but significant underperformance against the S&P 500. Technical indicators suggest an oversold condition, hinting at potential short-term upside, but the long-term outlook is uncertain due to the negative expected return (which needs clarification) and the volatility in equity and ROE figures.  The highly inconsistent ROE data warrants closer examination.  Before considering a long-term investment, it's crucial to address the data inconsistencies and thoroughly investigate the causes of the significant divergence between CL and the S&P 500, as well as the extreme ROE values.  Further due diligence, including a review of the company's financial statements and industry analysis, is necessary before any investment decision.  The -930.5% expected return is highly suspicious and needs to be reevaluated.
